This post was originally published on this site
LINKÖPING, Sweden, June 3, 2025 /PRNewswire/ — SyntheticMR AB (publ) is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology (AJNR), demonstrating the diagnostic equivalence—and potential advantages—of SyMRI® using the 3D-QALAS method compared to conventional 3D MRI in routine clinical neuroimaging.
The peer-reviewed study, available here, evaluated a large and diverse patient population across multiple imaging centers. The findings confirmed that 3D synthetic MRI using SyMRI matched conventional MRI in sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality.
“These results underscore the value of SyMRI in real-world clinical practice,” said Johanna Norén, Acting CEO of SyntheticMR. “With diagnostic performance on par with conventional imaging—and with added benefits in workflow efficiency and quantitative imaging—SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols.”
The study highlights SyMRI’s ability—particularly in 3D—to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a strong candidate for advancing scalable and standardized neuroimaging practices.
This clinical evidence further strengthens SyntheticMR’s mission to redefine MRI efficiency, bringing the power of objective, quantitative imaging into routine clinical use.
For additional information, please contact Johanna Noren, acting CEO, SyntheticMR AB, [email protected]; +46 70 619 21 00
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
SOURCE SyntheticMR AB
